Hepatocyte growth factor enhances the ability of dental pulp stem cells to ameliorate atherosclerosis in apolipoprotein E-knockout mice

IF 3.6 3区 医学 Q3 CELL & TISSUE ENGINEERING
H. Duan, Ning Tao, Lin Lv, Kai-Xin Yan, Yong-Gang You, Zhuang Mao, Chang-Yao Wang, Xue Li, Jia-Yan Jin, Chu-Tse Wu, Hua Wang
{"title":"Hepatocyte growth factor enhances the ability of dental pulp stem cells to ameliorate atherosclerosis in apolipoprotein E-knockout mice","authors":"H. Duan, Ning Tao, Lin Lv, Kai-Xin Yan, Yong-Gang You, Zhuang Mao, Chang-Yao Wang, Xue Li, Jia-Yan Jin, Chu-Tse Wu, Hua Wang","doi":"10.4252/wjsc.v16.i5.575","DOIUrl":null,"url":null,"abstract":"BACKGROUND\n Atherosclerosis (AS), a chronic inflammatory disease of blood vessels, is a major contributor to cardiovascular disease. Dental pulp stem cells (DPSCs) are capable of exerting immunomodulatory and anti-inflammatory effects by secreting cytokines and exosomes and are widely used to treat autoimmune and inflammation-related diseases. Hepatocyte growth factor (HGF) is a pleiotropic cytokine that plays a key role in many inflammatory and autoimmune diseases.\n AIM\n To modify DPSCs with HGF (DPSC-HGF) and evaluate the therapeutic effect of DPSC-HGF on AS using an apolipoprotein E-knockout (ApoE-/-) mouse model and an in vitro cellular model.\n METHODS\n ApoE-/- mice were fed with a high-fat diet (HFD) for 12 wk and injected with DPSC-HGF or Ad-Null modified DPSCs (DPSC-Null) through tail vein at weeks 4, 7, and 11, respectively, and the therapeutic efficacy and mechanisms were analyzed by histopathology, flow cytometry, lipid and glucose measurements, real-time reverse transcription polymerase chain reaction (RT-PCR), and enzyme-linked immunosorbent assay at the different time points of the experiment. An in vitro inflammatory cell model was established by using RAW264.7 cells and human aortic endothelial cells (HAOECs), and indirect co-cultured with supernatant of DPSC-Null (DPSC-Null-CM) or DPSC-HGF-CM, and the effect and mechanisms were analyzed by flow cytometry, RT-PCR and western blot. Nuclear factor-κB (NF-κB) activators and inhibitors were also used to validate the related signaling pathways.\n RESULTS\n DPSC-Null and DPSC-HGF treatments decreased the area of atherosclerotic plaques and reduced the expression of inflammatory factors, and the percentage of macrophages in the aorta, and DPSC-HGF treatment had more pronounced effects. DPSCs treatment had no effect on serum lipoprotein levels. The FACS results showed that DPSCs treatment reduced the percentages of monocytes, neutrophils, and M1 macrophages in the peripheral blood and spleen. DPSC-Null-CM and DPSC-HGF-CM reduced adhesion molecule expression in tumor necrosis factor-α stimulated HAOECs and regulated M1 polarization and inflammatory factor expression in lipopolysaccharide-induced RAW264.7 cells by inhibiting the NF-κB signaling pathway.\n CONCLUSION\n This study suggested that DPSC-HGF could more effectively ameliorate AS in ApoE-/- mice on a HFD, and could be of greater value in stem cell-based treatments for AS.","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of stem cells","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4252/wjsc.v16.i5.575","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Atherosclerosis (AS), a chronic inflammatory disease of blood vessels, is a major contributor to cardiovascular disease. Dental pulp stem cells (DPSCs) are capable of exerting immunomodulatory and anti-inflammatory effects by secreting cytokines and exosomes and are widely used to treat autoimmune and inflammation-related diseases. Hepatocyte growth factor (HGF) is a pleiotropic cytokine that plays a key role in many inflammatory and autoimmune diseases. AIM To modify DPSCs with HGF (DPSC-HGF) and evaluate the therapeutic effect of DPSC-HGF on AS using an apolipoprotein E-knockout (ApoE-/-) mouse model and an in vitro cellular model. METHODS ApoE-/- mice were fed with a high-fat diet (HFD) for 12 wk and injected with DPSC-HGF or Ad-Null modified DPSCs (DPSC-Null) through tail vein at weeks 4, 7, and 11, respectively, and the therapeutic efficacy and mechanisms were analyzed by histopathology, flow cytometry, lipid and glucose measurements, real-time reverse transcription polymerase chain reaction (RT-PCR), and enzyme-linked immunosorbent assay at the different time points of the experiment. An in vitro inflammatory cell model was established by using RAW264.7 cells and human aortic endothelial cells (HAOECs), and indirect co-cultured with supernatant of DPSC-Null (DPSC-Null-CM) or DPSC-HGF-CM, and the effect and mechanisms were analyzed by flow cytometry, RT-PCR and western blot. Nuclear factor-κB (NF-κB) activators and inhibitors were also used to validate the related signaling pathways. RESULTS DPSC-Null and DPSC-HGF treatments decreased the area of atherosclerotic plaques and reduced the expression of inflammatory factors, and the percentage of macrophages in the aorta, and DPSC-HGF treatment had more pronounced effects. DPSCs treatment had no effect on serum lipoprotein levels. The FACS results showed that DPSCs treatment reduced the percentages of monocytes, neutrophils, and M1 macrophages in the peripheral blood and spleen. DPSC-Null-CM and DPSC-HGF-CM reduced adhesion molecule expression in tumor necrosis factor-α stimulated HAOECs and regulated M1 polarization and inflammatory factor expression in lipopolysaccharide-induced RAW264.7 cells by inhibiting the NF-κB signaling pathway. CONCLUSION This study suggested that DPSC-HGF could more effectively ameliorate AS in ApoE-/- mice on a HFD, and could be of greater value in stem cell-based treatments for AS.
肝细胞生长因子增强牙髓干细胞改善载脂蛋白E基因敲除小鼠动脉粥样硬化的能力
背景 动脉粥样硬化(AS)是一种慢性血管炎症性疾病,是心血管疾病的主要诱因。牙髓干细胞(DPSC)能够通过分泌细胞因子和外泌体发挥免疫调节和抗炎作用,被广泛用于治疗自身免疫和炎症相关疾病。肝细胞生长因子(HGF)是一种多向性细胞因子,在许多炎症和自身免疫性疾病中起着关键作用。目的 用 HGF 改造 DPSC(DPSC-HGF),并利用载脂蛋白 E 基因敲除(ApoE-/-)小鼠模型和体外细胞模型评估 DPSC-HGF 对强直性脊柱炎的治疗效果。方法 用高脂饮食(HFD)喂养载脂蛋白E-/-小鼠12周,在第4、7和11周分别通过尾静脉注射DPSC-HGF或Ad-Null修饰的DPSCs(DPSC-Null),并通过组织病理学分析其疗效和机制、流式细胞术、血脂和血糖测定、实时逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附试验分析了不同时间点的疗效和机制。利用RAW264.7细胞和人主动脉内皮细胞(HAOECs)建立体外炎症细胞模型,并与DPSC-Null(DPSC-Null-CM)或DPSC-HGF-CM的上清液间接共培养,通过流式细胞术、RT-PCR和Western blot分析其作用和机制。核因子-κB(NF-κB)激活剂和抑制剂也用于验证相关信号通路。结果 DPSC-Null和DPSC-HGF处理可减少动脉粥样硬化斑块的面积,降低炎症因子的表达和巨噬细胞在主动脉中的比例,其中DPSC-HGF处理的效果更明显。DPSCs 处理对血清脂蛋白水平没有影响。FACS结果显示,DPSCs处理降低了外周血和脾脏中单核细胞、中性粒细胞和M1巨噬细胞的百分比。DPSC-Null-CM和DPSC-HGF-CM通过抑制NF-κB信号通路,减少了肿瘤坏死因子-α刺激的HAOECs中粘附分子的表达,并调节了脂多糖诱导的RAW264.7细胞中M1极化和炎症因子的表达。结论 本研究表明,DPSC-HGF能更有效地改善高脂血症载脂蛋白E-/-小鼠的强直性脊柱炎,在基于干细胞的强直性脊柱炎治疗中具有更大价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World journal of stem cells
World journal of stem cells Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
7.80
自引率
4.90%
发文量
750
期刊介绍: The World Journal of Stem Cells (WJSC) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of stem cells. It was launched on December 31, 2009 and is published monthly (12 issues annually) by BPG, the world''s leading professional clinical medical journal publishing company.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信